Unknown

Dataset Information

0

The progress made in determining the Mycobacterium tuberculosis structural proteome.


ABSTRACT: Mycobacterium tuberculosis is a highly infectious pathogen that is still responsible for millions of deaths annually. Effectively treating this disease typically requires a course of antibiotics, most of which were developed decades ago. These drugs are, however, not effective against persistent tubercle bacilli and the emergence of drug-resistant stains threatens to make many of them obsolete. The identification of new drug targets, allowing the development of new potential drugs, is therefore imperative. Both proteomics and structural biology have important roles to play in this process, the former as a means of identifying promising drug targets and the latter allowing understanding of protein function and protein-drug interactions at atomic resolution. The determination of M. tuberculosis protein structures has been a goal of the scientific community for the last decade, who have aimed to supply a large amount of structural data that can be used in structure-based approaches for drug discovery and design. Only since the genome sequence of M. tuberculosis has been available has the determination of large numbers of tuberculosis protein structures been possible. Currently, the molecular structures of 8.5% of all the pathogen's protein-encoding ORFs have been determined. In this review, we look at the progress made in determining the M. tuberculosis structural proteome and the impact this has had on the development of potential new drugs, as well as the discovery of the function of crucial mycobaterial proteins.

SUBMITTER: Ehebauer MT 

PROVIDER: S-EPMC3345573 | biostudies-literature | 2011 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

The progress made in determining the Mycobacterium tuberculosis structural proteome.

Ehebauer Matthias T MT   Wilmanns Matthias M  

Proteomics 20110614 15


Mycobacterium tuberculosis is a highly infectious pathogen that is still responsible for millions of deaths annually. Effectively treating this disease typically requires a course of antibiotics, most of which were developed decades ago. These drugs are, however, not effective against persistent tubercle bacilli and the emergence of drug-resistant stains threatens to make many of them obsolete. The identification of new drug targets, allowing the development of new potential drugs, is therefore  ...[more]

Similar Datasets

| S-EPMC3205055 | biostudies-literature
| S-EPMC4381106 | biostudies-literature
| S-EPMC3089889 | biostudies-literature
| S-EPMC3867987 | biostudies-literature
| S-EPMC2930474 | biostudies-literature
| S-EPMC2519606 | biostudies-literature
| S-EPMC6620280 | biostudies-literature
| S-EPMC2978697 | biostudies-literature
| S-EPMC2797603 | biostudies-literature
| S-EPMC4528245 | biostudies-literature